Every 10-Q that Cibus, Inc. (CBUS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CBUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBUS filings page.
Cibus, Inc. reported modest revenue growth but continued heavy losses for the quarter and six months ended June 30, 2026. Revenue was $994 thousand for the quarter and $2.7 million year-to-date, up 7% and 36% respectively, mainly from collaboration work in Sustainable Ingredients. Operating expenses fell sharply due to cost-cutting, with R&D down 30% and SG&A down 19% in the quarter, and no goodwill impairment charge in 2026 versus 2025.
Despite lower expenses, the business remains deeply loss-making. Net loss was $22.1 million for the quarter and $43.4 million year-to-date, and accumulated deficit reached $901.6 million. A large related-party royalty liability of $253.5 million generated $18.6 million of interest expense in six months. Cash used in operations was $20.9 million, leaving $20.4 million of cash against $14.4 million of current liabilities.
Management states that these factors raise substantial doubt about the company’s ability to continue as a going concern without new capital. Cibus raised roughly $33.4 million net in two follow-on equity offerings and established a $50 million ATM facility, and targets an annual cash usage run-rate of about $35 million exiting 2026 while advancing key Rice and Sustainable Ingredients programs.
Cibus, Inc. reported first-quarter 2026 revenue of $1.7 million, up from $1.0 million a year earlier, mainly from collaboration work in sustainable ingredients. Net loss narrowed to $21.2 million from $49.4 million, helped by lower research, selling, and litigation costs and no goodwill impairment this year.
Cash and cash equivalents rose to $30.3 million as of March 31, 2026, after two equity offerings that brought in about $33.4 million of net proceeds. The company used $11.5 million of cash in operating activities in the quarter and targets annual net cash usage of about $30 million or less in 2026.
Management discloses substantial doubt about Cibus’ ability to continue as a going concern over the next year without new capital. A large related-party Royalty Liability of $244.0 million, carrying a 16.5% effective yield and generating $9.1 million of quarterly interest expense, continues to weigh on results as the company remains pre-royalty and pre-profit.
Cibus, Inc. filed its Q3 2025 10‑Q, reporting continued operating losses and a going concern warning. Revenue was $615 thousand for the quarter and $2.6 million year‑to‑date, reflecting limited current commercialization. Quarterly net loss was $24.3 million; year‑to‑date net loss was $100.3 million.
Cash and cash equivalents were $23.9 million as of September 30, 2025, against $20.6 million in current liabilities. Management states that additional capital will be needed within a year to support plans. The company raised net proceeds of approximately $21.4 million in January 2025 and $25.0 million in June 2025 follow‑on offerings and terminated its prior ATM facility without 2025 sales.
Year‑to‑date operating expenses totaled $77.5 million, including a $20.9 million goodwill impairment recognized in Q1. A July workforce reduction of ~34 roles incurred $0.2 million in severance in Q3. As of November 10, 2025, the company reported 54,283,111 shares outstanding across Class A and Class B.
Cibus, Inc. reported continued losses and liquidity pressure while narrowing its operational focus to commercialize rice herbicide-tolerance traits. The company recorded a $76.0 million net loss for the six months ended June 30, 2025, and used $25.4 million of cash in operating activities during that period. Cash and cash equivalents were $36.5 million versus current liabilities of $22.4 million, and an accumulated deficit of $803.4 million. Management expects to continue incurring losses and needs additional capital within a year; this raises substantial doubt about the companys ability to continue as a going concern. Cibus implemented cost reductions and a restructuring, targets annual net cash usage of approximately $30.0 million by 2026, and is prioritizing Rice weed-management traits that it estimates could represent >$200 million of annual accessible royalties upon full commercialization. The company recognized a $21.0 million goodwill impairment in Q1 2025 and completed equity transactions in Jan and Jun 2025 to raise net proceeds of about $46.4 million combined.